Catalyst Pharmaceuticals Inc Earnings

The next earnings date for Catalyst Pharmaceuticals Inc is March 18, 2026.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Catalyst Pharmaceuticals Inc Earnings

Report DateEstimated Earnings Per Share
03/18/2026$0.30

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Catalyst Pharmaceuticals Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
11/05/2025---$0-100.00%
08/06/2025---$0-100.00%
05/06/2025Before Market$0.6829.11%
02/26/2025After Market$0.70118.75%
11/06/2024After Market$0.3516.67%
08/07/2024After Market$0.3326.92%
05/08/2024After Market$0.1911.76%
02/28/2024After Market$0.3114.81%
11/08/2023After Market$-0.29-3.57%
08/09/2023After Market$0.5326.19%
05/10/2023After Market$0.26-18.75%
03/15/2023After Market$0.224.76%
11/09/2022After Market$0.205.26%
08/09/2022After Market$0.2017.65%
05/10/2022After Market$0.12-14.29%
03/16/2022After Market$0.09-25.00%
11/09/2021After Market$0.100.00%
08/09/2021After Market$0.1110.00%
05/10/2021After Market$0.07-22.22%
03/15/2021After Market$0.1122.22%
11/09/2020After Market$0.1110.00%
08/10/2020After Market$0.090.00%
05/11/2020After Market$0.1011.11%
03/16/2020After Market$0.08-20.00%
11/12/2019After Market$0.1318.18%
08/07/2019After Market$0.10233.33%
05/10/2019After Market$-0.0192.31%
03/18/2019After Market$-0.14-27.27%
11/07/2018After Market$-0.08-14.29%
08/07/2018After Market$-0.0614.29%
05/09/2018After Market$-0.060.00%
03/14/2018After Market$-0.060.00%
11/08/2017After Market$-0.050.00%
08/09/2017After Market$-0.0516.67%
05/10/2017After Market$-0.060.00%
03/15/2017After Market$-0.0528.57%
11/09/2016After Market$-0.0516.67%
08/09/2016After Market$-0.0614.29%
05/10/2016After Market$-0.070.00%
03/15/2016After Market$-0.070.00%
11/09/2015After Market$-0.0528.57%
08/10/2015After Market$-0.0614.29%
05/11/2015After Market$-0.0633.33%
03/16/2015Before Market$-0.0528.57%
11/13/2014After Market$-0.07-40.00%
08/13/2014---$-0.0528.57%
05/15/2014---$-0.07-16.67%
03/19/2014---$-0.0271.43%
11/14/2013---$-0.13-85.71%
08/15/2013---$-0.08-33.33%
05/14/2013---$-0.0442.86%
11/15/2012---$-0.08-166.67%
08/15/2012---$-0.0175.00%
05/16/2012---$-0.0450.00%
11/15/2011---$-0.0528.57%
08/16/2011---$-0.0625.00%
04/01/2011---$-0.0442.86%
03/31/2011---$-0.0442.86%
11/16/2010---$-0.0537.50%
08/13/2010---$-0.070.00%
05/17/2010---$-0.06-50.00%
03/31/2010---$-0.06-20.00%
11/12/2009---$-0.0910.00%
08/07/2009---$-0.1335.00%
05/14/2009---$-0.228.33%
03/26/2009---$-0.27-17.39%
11/14/2008---$-0.224.35%
08/15/2008---$-0.19---
05/16/2008---$-0.13-8.33%
03/26/2008---$-0.08-14.29%
11/14/2007---$-0.0662.50%
08/10/2007---$-0.1028.57%
05/14/2007---$-0.1044.44%
12/16/2006---$-0.27---

More About Catalyst Pharmaceuticals Inc

Country
USA
Full Time Employees
181

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Catalyst Pharmaceuticals Inc Earnings” Can Refer to the Catalyst Pharmaceuticals Inc Earnings Date

Some people say “Catalyst Pharmaceuticals Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Catalyst Pharmaceuticals Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Catalyst Pharmaceuticals Inc Stock on the Earnings Date

If you own Catalyst Pharmaceuticals Inc stock (CPRX) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Catalyst Pharmaceuticals Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Catalyst Pharmaceuticals Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Catalyst Pharmaceuticals Inc Earnings

You can contact us any time if you would like to ask questions about Catalyst Pharmaceuticals Inc earnings or anything else related to the stock market.